Cargando…

Quality assessment of nine paracetamol 500 mg tablet brands marketed in Saudi Arabia

OBJECTIVE: To evaluate in-vitro quality of paracetamol 500 mg tablet brands marketed in Saudi Arabia. RESULTS: Two reference (R1 and R2) and seven generic (G1-G7) brands were commercially available. Four brands were single-drug, containing paracetamol only (R1, G1-G3) and five contained additional a...

Descripción completa

Detalles Bibliográficos
Autores principales: AlSwayeh, Reem, Alvi, Syed N., Hammami, Muhammad M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247153/
https://www.ncbi.nlm.nih.gov/pubmed/34193274
http://dx.doi.org/10.1186/s13104-021-05672-y
_version_ 1783716461737410560
author AlSwayeh, Reem
Alvi, Syed N.
Hammami, Muhammad M.
author_facet AlSwayeh, Reem
Alvi, Syed N.
Hammami, Muhammad M.
author_sort AlSwayeh, Reem
collection PubMed
description OBJECTIVE: To evaluate in-vitro quality of paracetamol 500 mg tablet brands marketed in Saudi Arabia. RESULTS: Two reference (R1 and R2) and seven generic (G1-G7) brands were commercially available. Four brands were single-drug, containing paracetamol only (R1, G1-G3) and five contained additional active ingredients (R2, G4-G7). All brands were immediate-release. Weight variation (n = 20, range as percent difference from mean), active substance content (n = 20, mean (SD) as percent difference from label), breaking force (n = 10, mean (SD)), and friability (n = 20, as percent weight loss) ranged from 97 to 102%, 96.1% (2.9%) to 99.8% (1.1%), 9.9 (0.4) to 21.0 (0.9) kg, and 0.017% to 0.809%, respectively. Disintegration (water medium) time (n = 6, minute: second) ranged from 02:35–03:09 to 12:49–13:10. Dissolution (phosphate buffer, pH 5.8) profile showed a mean release at 30 min of 87% to 97% of label content, with seven brands passing stage-1 (≥ 85% for each of 6 test units) and two passing stage-2 (mean of 12 test units ≥ 85%) criteria. Despite statistically significant differences between R1 and R2 and some of their corresponding generic brands in active substance content, breaking force, and amount dissolved at 30 min, all nine brands met the pre-specified quality standards. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-021-05672-y.
format Online
Article
Text
id pubmed-8247153
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82471532021-07-06 Quality assessment of nine paracetamol 500 mg tablet brands marketed in Saudi Arabia AlSwayeh, Reem Alvi, Syed N. Hammami, Muhammad M. BMC Res Notes Research Note OBJECTIVE: To evaluate in-vitro quality of paracetamol 500 mg tablet brands marketed in Saudi Arabia. RESULTS: Two reference (R1 and R2) and seven generic (G1-G7) brands were commercially available. Four brands were single-drug, containing paracetamol only (R1, G1-G3) and five contained additional active ingredients (R2, G4-G7). All brands were immediate-release. Weight variation (n = 20, range as percent difference from mean), active substance content (n = 20, mean (SD) as percent difference from label), breaking force (n = 10, mean (SD)), and friability (n = 20, as percent weight loss) ranged from 97 to 102%, 96.1% (2.9%) to 99.8% (1.1%), 9.9 (0.4) to 21.0 (0.9) kg, and 0.017% to 0.809%, respectively. Disintegration (water medium) time (n = 6, minute: second) ranged from 02:35–03:09 to 12:49–13:10. Dissolution (phosphate buffer, pH 5.8) profile showed a mean release at 30 min of 87% to 97% of label content, with seven brands passing stage-1 (≥ 85% for each of 6 test units) and two passing stage-2 (mean of 12 test units ≥ 85%) criteria. Despite statistically significant differences between R1 and R2 and some of their corresponding generic brands in active substance content, breaking force, and amount dissolved at 30 min, all nine brands met the pre-specified quality standards. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-021-05672-y. BioMed Central 2021-06-30 /pmc/articles/PMC8247153/ /pubmed/34193274 http://dx.doi.org/10.1186/s13104-021-05672-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Note
AlSwayeh, Reem
Alvi, Syed N.
Hammami, Muhammad M.
Quality assessment of nine paracetamol 500 mg tablet brands marketed in Saudi Arabia
title Quality assessment of nine paracetamol 500 mg tablet brands marketed in Saudi Arabia
title_full Quality assessment of nine paracetamol 500 mg tablet brands marketed in Saudi Arabia
title_fullStr Quality assessment of nine paracetamol 500 mg tablet brands marketed in Saudi Arabia
title_full_unstemmed Quality assessment of nine paracetamol 500 mg tablet brands marketed in Saudi Arabia
title_short Quality assessment of nine paracetamol 500 mg tablet brands marketed in Saudi Arabia
title_sort quality assessment of nine paracetamol 500 mg tablet brands marketed in saudi arabia
topic Research Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247153/
https://www.ncbi.nlm.nih.gov/pubmed/34193274
http://dx.doi.org/10.1186/s13104-021-05672-y
work_keys_str_mv AT alswayehreem qualityassessmentofnineparacetamol500mgtabletbrandsmarketedinsaudiarabia
AT alvisyedn qualityassessmentofnineparacetamol500mgtabletbrandsmarketedinsaudiarabia
AT hammamimuhammadm qualityassessmentofnineparacetamol500mgtabletbrandsmarketedinsaudiarabia